UroGen Pharma announced the successful completion of its new drug application, or NDA, submission for investigational drug UGN-102, for intravesical solution. UroGen anticipates potential FDA approval in early 2025, if the NDA is accepted for filing by the FDA and priority review is granted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Is URGN a Buy, Before Earnings?
- UroGen Pharma Shareholders Shape Governance and Incentives
- UroGen Pharma 5M share Spot Secondary priced at $17.50
- UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Pharma announces offering of ordinary shares, warrants
Questions or Comments about the article? Write to editor@tipranks.com